Effect of pramlintide treatment on markers of cardiovascular risk in patients with type 2 diabetes using basal insulin

被引：0
|
作者：
Lush, C. [1 ]
Zhang, B. [1 ]
Maggs, D. [1 ]
Darsow, T. [1 ]
Kolterman, O. [1 ]
机构：
[1] Amylin Pharmaceut Inc, San Diego, CA USA
来源：
DIABETOLOGIA | 2007年 / 50卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1258
引用
收藏
页码：S514 / S514
页数：1
相关论文
共 50 条
  • [21] Patients with Type I diabetes: perceptions associated with pramlintide as an adjunctive treatment to insulin
    Marrero, D
    Kruger, D
    Burrell, T
    Gloster, M
    Crean, J
    Herrmann, K
    Maggs, D
    Kolterman, O
    [J]. DIABETOLOGIA, 2004, 47 : A283 - A283
  • [22] Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients
    Hollander, P
    Maggs, DG
    Ruggles, JA
    Fineman, M
    Shen, L
    Kolterman, OG
    Weyer, C
    [J]. OBESITY RESEARCH, 2004, 12 (04): : 661 - 668
  • [23] Does addition of pramlintide to basal insulin improve glycemic control in type 2 diabetes mellitus?
    Edelman, Steven V.
    [J]. NATURE CLINICAL PRACTICE ENDOCRINOLOGY & METABOLISM, 2008, 4 (04): : 194 - 195
  • [24] Does addition of pramlintide to basal insulin improve glycemic control in type 2 diabetes mellitus?
    Steven V Edelman
    [J]. Nature Clinical Practice Endocrinology & Metabolism, 2008, 4 : 194 - 195
  • [25] Effect of cardiovascular risk management on endothelial markers in type 2 diabetes
    Brown, LF
    Maxwell, PR
    Panarelli, M
    [J]. CLINICA CHIMICA ACTA, 2005, 355 : S346 - S346
  • [26] Effect of adjunctive pramlintide treatment on treatment satisfaction in patients with type 1 diabetes
    Marrero, David G.
    Herrmann, Kathrin
    Crean, John
    Rubin, Richard
    Zhang, Bei
    Fineberg, Naomi
    Kellmeyer, Terrie
    Kolterman, Orville
    Gloster, Maurice
    [J]. DIABETES CARE, 2007, 30 (02) : 210 - 216
  • [27] Optimal insulin treatment for patients with type 2 diabetes - Basal or prandial insulin supplementation?
    Jermendy, Gyorgy
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2006, 74 : S20 - S29
  • [28] The role of basal insulin in the treatment of type 2 diabetes
    Antsiferov, M. B.
    Petraneva, E. V.
    [J]. DIABETES MELLITUS, 2006, 9 (04): : 19 - 22
  • [29] Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus
    Tuepker, J
    [J]. CIRCULATION, 2003, 107 (16) : E109 - E109
  • [30] Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus
    Haffner, SM
    Greenberg, AS
    Weston, WM
    Chen, HZ
    Williams, K
    Freed, MI
    [J]. CIRCULATION, 2002, 106 (06) : 679 - 684
12345